HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

Clinical Cancer Research- United States

doi 10.1158/1078-0432.ccr-18-0198

Full Text

Abstract

Available in

Date

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research
Cancer ResearchOncology
2018English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology
MedicinePharmacology
2011English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Small Enterprises’ Predisposition to Adopt an Erp

2004English

P3.13-35 Antitumor Effect of Neratinib Targeting HER2-Altered Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-56 Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Guidelines to Adopt an Applicable SIEM Solution

Journal of Information Security
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy